Home / Peptides / Orforglipron

Orforglipron (Foundayo) Dosage: Label Schedule and Status

FDA-approved pill

Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.

Also called: Foundayo, LY3502970

Regulatory status (US)

FDA-approved on April 1, 2026 as Foundayo (Eli Lilly) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It has no type 2 diabetes indication on the current label.

What it is

An oral, small-molecule GLP-1 receptor agonist taken once a day with no food or water restrictions. It is not a peptide, so there is nothing to reconstitute and no syringe math.

Label dose escalation (Foundayo tablets)

StepDaily doseNote
10.8 mgAt least 30 days
22.5 mgAt least 30 days
35.5 mgMay stay here
49 mgMaximum with strong CYP3A4 inhibitors
514.5 mg
617.2 mgMaximum dose

From the Foundayo prescribing information; at least 30 days at each step. If 7 or more doses in a row are missed, the label says to re-escalate.

Orforglipron is not mixed with water and drawn into a syringe, so the reconstitution calculator does not apply.

What human studies show

Safety

Compare

Questions

Is Orforglipron FDA-approved?
FDA-approved on April 1, 2026 as Foundayo (Eli Lilly) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It has no type 2 diabetes indication on the current label.
What dose of Orforglipron has been studied?
1: 0.8 mg: At least 30 days; 2: 2.5 mg: At least 30 days; 3: 5.5 mg: May stay here; 4: 9 mg: Maximum with strong CYP3A4 inhibitors; 5: 14.5 mg; 6: 17.2 mg: Maximum dose. From the Foundayo prescribing information; at least 30 days at each step. If 7 or more doses in a row are missed, the label says to re-escalate.

Related

Tirzepatide

Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.

Semaglutide

Weekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).

Tesamorelin

GHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.

Elamipretide (SS-31)

Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.

Sources

  1. Foundayo (orforglipron) US prescribing information, Eli Lilly
  2. Healio: FDA approves orforglipron, an oral GLP-1, for adults with obesity (Apr 2026)

Last checked 2026-11-16. How we pick and check sources: methodology.